Response to: Correspondence on "Associations of baseline use of biologic or targeted synthetic DMARDs with COVID-19 severity in rheumatoid arthritis: results from the COVID-19 Global Rheumatology Alliance physician registry" by Sparks <i>et al</i>.

Wallace, Zachary S; Sparks, Jeffrey A; Robinson, Philip C; Machado, Pedro M; Yazdany, Jinoos

Response to: Correspondence on "Associations of baseline use of biologic or targeted synthetic DMARDs with COVID-19 severity in rheumatoid arthritis: results from the COVID-19 Global Rheumatology Alliance physician registry" by Sparks et al.

Wallace, Zachary S; Sparks, Jeffrey A; Robinson, Philip C; Machado, Pedro M; Yazdany, Jinoos.

Afiliación

Wallace ZS; Massachusetts General Hospital, Boston, Massachusetts, USA.
Sparks JA; Harvard Medical School, Boston, Massachusetts, USA.
Robinson PC; Department of Medicine, Division of Rheumatology, Inflammation, and Immunity, Brigham and Women's Hospital, Boston, Massachusetts, USA jsparks@bwh.harvard.edu.
Machado PM; Medicine, Harvard Medical School, Boston, Massachusetts, USA.
Yazdany J; Faculty of Medicine, The University of Queensland, Herston, Queensland, Australia.

Ann Rheum Dis ; 82(7): e158, 2023 07.

Article en En | MEDLINE | ID: mdl-34426400

Asunto(s)

Antirreumáticos; Artritis Reumatoide; Productos Biológicos; COVID-19; Reumatología; Humanos; Antirreumáticos/uso terapéutico; Artritis Reumatoide/tratamiento farmacológico; Productos Biológicos/uso terapéutico

Palabras clave

COVID-19; antirheumatic agents; biological therapy

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Artritis Reumatoide / Reumatología / Productos Biológicos / Antirreumáticos / COVID-19 Tipo de estudio: Risk_factors_studies Límite: Humans Idioma: En Revista: Ann Rheum Dis Año: 2023 Tipo del documento: Article País de afiliación: Estados Unidos

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google